Observing the effects of selinexor for treating Non-Hodgkin lymphoma
A Real-world Study: Efficacy and Safety of Selinexor-based Regimens for Non-Hodgkin Lymphoma
This study looks at how well the drug selinexor works and its safety for people with Non-Hodgkin lymphoma who have recently been treated with it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 3 sites (Shanghai, Shanghai and 2 other locations) |
| Trial ID | NCT05852028 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the efficacy and safety of selinexor-based regimens in patients diagnosed with DLBCL or T cell lymphoma. It collects real-world data from clinical practice, including patient demographics, tumor characteristics, treatment history, and adverse reactions. The study focuses on patients who have received selinexor therapy within the last three months, allowing for a comprehensive analysis of treatment outcomes in a real-world setting.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with clinically confirmed DLBCL or T/NK cell lymphoma who have used selinexor-based therapy in the past three months.
Not a fit: Patients who have previously received selinexor or those deemed unsuitable for enrollment by their physicians may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effectiveness of selinexor for patients with Non-Hodgkin lymphoma, potentially leading to improved treatment strategies.
How similar studies have performed: While this study utilizes a real-world observational approach, similar studies have shown promise in evaluating treatment efficacy in lymphoma, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Know and voluntarily sign the Informed Consent Form (ICF) * Clinically confirmed DLBCL, T or NK cell lymphoma * Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy in the past 3 months are included * Cooperate with clinical diagnosis and treatment management, and provide disease-related past medical history materials Exclusion Criteria: * Previously received selinexor * Poor patient compliance * physicians evaluate that patients are not suitable for enrollment
Where this trial is running
Shanghai, Shanghai and 2 other locations
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai, China (Recruiting)
- The First Affiliated Hospital of Soochow University — Suzhou, China (Recruiting)
- Union Hospital Affiliated to Huazhong University of Science and Technology — Wuhan, China (Recruiting)
Study contacts
- Study coordinator: Weili Zhao, Prof.
- Email: zwl_trial@163.com
- Phone: +862164370045
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.